Patent Grant
11944334
The present technology relates generally to devices and methods for removing obstructions from body lumens. Some embodiments of the present technology relate to devices and methods for electrically enhanced removal of clot material from blood vessels.
Many medical procedures use medical device(s) to remove an obstruction (such as clot material) from a body lumen, vessel, or other organ. An inherent risk in such procedures is that mobilizing or otherwise disturbing the obstruction can potentially create further harm if the obstruction or a fragment thereof dislodges from the retrieval device. If all or a portion of the obstruction breaks free from the device and flows downstream, it is highly likely that the free material will become trapped in smaller and more tortuous anatomy. In many cases, the physician will no longer be able to use the same retrieval device to again remove the obstruction because the device may be too large and/or immobile to move the device to the site of the new obstruction.
Procedures for treating ischemic stroke by restoring flow within the cerebral vasculature are subject to the above concerns. The brain relies on its arteries and veins to supply oxygenated blood from the heart and lungs and to remove carbon dioxide and cellular waste from brain tissue. Blockages that interfere with this blood supply eventually cause the brain tissue to stop functioning. If the disruption in blood occurs for a sufficient amount of time, the continued lack of nutrients and oxygen causes irreversible cell death. Accordingly, it is desirable to provide immediate medical treatment of an ischemic stroke.
To access the cerebral vasculature, a physician typically advances a catheter from a remote part of the body (typically a leg) through the abdominal vasculature and into the cerebral region of the vasculature. Once within the cerebral vasculature, the physician deploys a device for retrieval of the obstruction causing the blockage. Concerns about dislodged obstructions or the migration of dislodged fragments increases the duration of the procedure at a time when restoration of blood flow is paramount. Furthermore, a physician might be unaware of one or more fragments that dislodge from the initial obstruction and cause blockage of smaller more distal vessels.
Many physicians currently perform thrombectomies (i.e. clot removal) with stents to resolve ischemic stroke. Typically, the physician deploys a stent into the clot in an attempt to push the clot to the side of the vessel and re-establish blood flow. Tissue plasminogen activator (“tPA”) is often injected into the bloodstream through an intravenous line to break down a clot. However, it takes time for the tPA to reach the clot because the tPA must travel through the vasculature and only begins to break up the clot once it reaches the clot material. tPA is also often administered to supplement the effectiveness of the stent. Yet, if attempts at clot dissolution are ineffective or incomplete, the physician can attempt to remove the stent while it is expanded against or enmeshed within the clot. In doing so, the physician must effectively drag the clot through the vasculature, in a proximal direction, into a guide catheter located within vessels in the patient's neck (typically the carotid artery). While this procedure has been shown to be effective in the clinic and easy for the physician to perform, there remain some distinct disadvantages to using this approach.
For example, one disadvantage is that the stent may not sufficiently retain the clot as it pulls the clot to the catheter. In such a case, some or all of the clot might remain in the vasculature. Another risk is that, as the stent mobilizes the clot from the original blockage site, the clot might not adhere to the stent as the stent is withdrawn toward the catheter. This is a particular risk when passing through bifurcations and tortuous anatomy. Furthermore, blood flow can carry the clot (or fragments of the clot) into a branching vessel at a bifurcation. If the clot is successfully brought to the end of the guide catheter in the carotid artery, yet another risk is that the clot may be “stripped” or “sheared” from the stent as the stent enters the guide catheter.
In view of the above, there remains a need for improved devices and methods that can remove occlusions from body lumens and/or vessels.
Mechanical thrombectomy (i.e., clot-grabbing and removal) has been effectively used for treatment of ischemic stroke. Although most clots can be retrieved in a single pass attempt, there are instances in which multiple attempts are needed to fully retrieve the clot and restore blood flow through the vessel. Additionally, there exist complications due to detachment of the clot from the interventional element during the retrieval process as the interventional element and clot traverse through tortuous intracranial vascular anatomy. For example, the detached clot or clot fragments can obstruct other arteries leading to secondary strokes. The failure modes that contribute to clot release during retrieval are: (a) boundary conditions at bifurcations; (b) changes in vessel diameter; and (c) vessel tortuosity, amongst others.
Certain blood components, such as platelets and coagulation proteins, display negative electrical charges. The treatment systems of the present technology provide an interventional element and a current generator configured to positively charge the interventional element during one or more stages of a thrombectomy procedure. For example, the current generator may apply a constant or pulsatile direct current (DC) to the interventional element. The positively charged interventional element attracts negatively charged blood components, thereby improving attachment of the thrombus to the interventional element and reducing the number of device passes or attempts necessary to fully retrieve the clot. In some aspects of the present technology, the treatment system includes a core member extending between the current generator and the interventional element. A delivery electrode may be integrated into the core member, and the treatment system further includes a return electrode that may be disposed at a number of different locations. For example, the return electrode can be a needle, a grounding pad, a conductive element carried by a one or more catheters of the treatment system, a guide wire, and/or any other suitable conductive element configured to complete an electrical circuit with the delivery electrode and the extracorporeally positioned current generator. When the interventional element is placed in the presence of blood (or any other electrolytic medium) and voltage is applied at the terminals of the current generator, current flows along the core member to the interventional element, through the blood, and to the return electrode, thereby positively charging at least a portion of the interventional element and adhering clot material thereto.
While applying a current to positively charge the interventional element can improve attachment of the thrombus to the interventional element, the inventors have discovered particularly effective waveforms and power delivery parameters for promoting thrombus attachment. It is important to provide sufficient current and power to enhance clot-adhesion without ablating tissue or generating new clots (i.e., the delivered power should not be significantly thrombogenic). The clot-adhesion effect appears to be driven by the peak current of the delivered electrical signal. Periodic (e.g., pulse-width modulated or pulsed direct current) waveforms can advantageously provide the desired peak current without delivering excessive total energy. In particular, non-square periodic waveforms can be especially effective in providing the desired peak current without delivering excessive total energy or electrical charge to the interventional element. In some embodiments, the overall charge delivered can be between about 30-1200 mC, the total energy delivered can be between about 120-24,000 mJ, and/or the peak current delivered can be between about 0.5-5 mA. In at least some embodiments, the duration of energy delivery can be between 30 seconds and 5 minutes, and in some embodiments no more than 2 minutes.
The treatment systems and methods of the present technology can further improve adhesion of the clot to the interventional element by varying features of the interventional element. For example, in some embodiments, some or all of the interventional element can be coated with one or more highly conductive materials, such as gold, to improve clot adhesion. In some aspects of the present technology, a working length of the interventional element may be coated with the conductive material while a non-working length of the interventional element may be coated with an insulative material.
Treatment systems and methods disclosed herein may also improve clot adhesion by modifying the environment at the treatment site. For example, the inventors have observed that blood flow at the treatment site reduces adhesion forces between clot material and the interventional element, even when the interventional element is positively charged. To address this loss of adhesion, the present technology provides systems and methods for arresting blood flow at the treatment site at least while supplying electrical energy to the treatment site. In addition, the present technology provides systems and methods for infusing certain fluids (such as saline and/or contrast) at the treatment site at least during energy delivery to improve conductivity at the treatment site for electrically enhanced clot adhesion.
Many of the treatment systems of the present technology include an aspiration catheter for applying negative pressure at the treatment site to secure the clot against a distal portion of the aspiration catheter (and/or other component of the treatment system). Aspiration also helps capture any newly formed clots to reduce the risk of downstream embolism. Suction may be applied before, during, and/or after supplying electrical energy to the interventional element. In some embodiments, a distal portion of the aspiration catheter may be configured for electrically enhanced clot adhesion such that clot engagement and retrieval may be performed without a separate interventional element. For example, in some aspects of the technology, the aspiration catheter may include a delivery electrode at its distal tip that is configured to be positively charged by the current generator. A return electrode may be disposed at a number of different locations, such as the aspiration catheter or another component of the treatment system (such as a guide catheter). Securement of the clot to the aspiration catheter via suction may be enhanced by the additional adhesion forces generated when the delivery electrode is positively charged.
The present technology is illustrated, for example, according to various aspects described below. Various examples of aspects of the present technology are described as numbered clauses (1, 2, 3, etc.) for convenience. These are provided as examples and do not limit the present technology. It is noted that any of the dependent clauses may be combined in any combination, and placed into a respective independent clause, e.g., clause (1, 23, 35, etc.). The other clauses can be presented in a similar manner.
Clause 1. A thrombectomy system, comprising:
Clause 2. The thrombectomy system of Clause 1, wherein the power source is configured to be extracorporeally positioned while the interventional element is positioned at or near the thrombus.
Clause 3. The thrombectomy system of Clause 1 or Clause 2, wherein an electrical conductivity of the second metallic material is greater than an electrical conductivity of the first metallic material.
Clause 4. The thrombectomy system of any one of Clauses 1 to 3, wherein the first metallic material is a superelastic alloy and the second metallic material is gold.
Clause 5. The thrombectomy system of any one of Clauses 1 to 4, wherein the first metallic material has a surface including an outward-facing portion that faces away from a central lumen of the interventional element, and wherein the second metallic material is disposed on the first metallic material only at the outward-facing portion and not at a remaining portion of the surface.
Clause 6. The thrombectomy system of any one of Clauses 1 to 5, wherein the interventional element comprises a working length portion and a non-working length portion, the working length portion being configured to interlock, capture, and/or engage a thrombus.
Clause 7. The thrombectomy system of Clause 6, wherein a distal terminus of the working length portion is proximal of a distal terminus of the interventional element.
Clause 8. The thrombectomy system of Clause 6 or Clause 7, wherein the working length portion is spaced apart from a distal terminus of the interventional element.
Clause 9. The thrombectomy system of any one of Clauses 6 to 8, wherein the non-working length portion is disposed between a distal end of the elongated member and a proximal end of the working length portion.
Clause 10. The thrombectomy system of any one of Clauses 6 to 9, wherein the second metallic material has a greater conductivity than the first metallic material and is disposed on the first metallic material only along the working length portion of the interventional element and not along the non-working length portion.
Clause 11. The thrombectomy system of any one of Clauses 6 to 10, wherein the second metallic material has a greater conductivity than the first metallic material and is disposed on the first metallic material only along the working length portion of the interventional element and not along (i) the non-working length portion and (ii) a distal-most region of the interventional element.
Clause 12. The thrombectomy system of any one of Clauses 6 to 11, wherein the non-working length portion is covered by a non-conductive and/or insulative material such that the non-working length portion is not in electrical contact with the surrounding media when the interventional element is deployed within a blood vessel.
Clause 13. The thrombectomy system of any one of Clauses 6 to 11, wherein the non-working length portion and a region of the interventional element distal of the working length portion are covered by a non-conductive and/or insulative material such that the non-working length portion and the region are not in electrical contact with the surrounding media when the interventional element is deployed within a blood vessel.
Clause 14. The thrombectomy system of any one of Clauses 6 to 11, wherein the second metallic material is selectively disposed on the first metallic material such that the delivered current is concentrated along the working length portion.
Clause 15. The thrombectomy system of any one of Clauses 1 to 14, wherein the power source is configured to deliver direct current to the interventional element.
Clause 16. The thrombectomy system of any one of Clauses 1 to 15, wherein the power source is configured to deliver pulsatile current to the interventional element.
Clause 17. The thrombectomy system of any one of Clauses 1 to 16, wherein the current is a constant current having an amplitude of between about 0.5 mA and about 5 mA.
Clause 18. The thrombectomy system of any one of Clauses 1 to 17, wherein the interventional element comprises a thrombectomy device.
Clause 19. The thrombectomy system of any one of Clauses 1 to 18, wherein the interventional element comprises a stent retriever.
Clause 20. The thrombectomy system of any one of Clauses 1 to 19, wherein the interventional element comprises a removal device.
Clause 21. The thrombectomy system of any one of Clauses 1 to 20, wherein the interventional element is a mesh.
Clause 22. The thrombectomy system of any one of Clauses 1 to 21, wherein the interventional element is a laser-cut stent.
Clause 23. A thrombectomy system, comprising:
Clause 24. The thrombectomy system of Clause 23, wherein the first catheter includes a flow arrest element configured to expand within the vessel lumen and at least partially arrest blood flow proximal of the thrombus.
Clause 25. The thrombectomy system Clause 23 or Clause 24, wherein the first catheter is a guide catheter and the second catheter is a microcatheter.
Clause 26. The thrombectomy system of any one of Clauses 23 to 25, wherein the thrombectomy system further includes a third catheter configured to be slidably received through the lumen of the first catheter.
Clause 27. The thrombectomy system of Clause 26, wherein the second catheter is configured to be slidably received within a lumen of the second catheter.
Clause 28. The thrombectomy system of Clause 26, wherein the first catheter is a guide catheter and the third catheter is a distal access catheter.
Clause 29. The thrombectomy system of Clause 26, wherein the first catheter is a guide catheter, the second catheter is a microcatheter, and the third catheter is a distal access catheter.
Clause 30. The thrombectomy system of Clause 26, wherein the third catheter is an aspiration catheter.
Clause 31. The thrombectomy system of Clause 26, wherein the first catheter is a balloon guide catheter and the third catheter is a distal access catheter.
Clause 32. The thrombectomy system Clause 26, wherein the first catheter is a guide catheter and the third catheter is a distal access catheter, wherein the distal access catheter includes a flow arrest element configured to expand within the vessel lumen and at least partially arrest blood flow proximal of the thrombus.
Clause 33. The thrombectomy system of Clause 32, wherein the distal access catheter is an aspiration catheter.
Clause 34. The thrombectomy system of any one of Clauses 26 to 33, wherein:
Clause 35. A method, comprising:
Clause 36. The method of Clause 35, further comprising concentrating the positive charge along a working length of the interventional element, wherein a proximal end of the working length is distal of a proximal end of the interventional element and a distal end of the working length is proximal of a distal end of the interventional element.
Clause 37. The method of any one of Clauses 35 to 36, wherein producing a positive charge includes delivering a direct current to the interventional element from the power source.
Clause 38. The method of any one of Clauses 35 to 37, wherein producing a positive charge includes delivering a pulsatile current to the interventional element from the power source.
Clause 39. The method of any one of Clauses 35 to 38, wherein an electrical conductivity of the second metallic material is greater than an electrical conductivity of the first metallic material.
Clause 40. The method of any one of Clauses 35 to 39, wherein the second metallic material is gold.
Clause 41. The method of any one of Clauses 35 to 40, wherein producing a positive charge includes delivering a current to the interventional element, the current having an amplitude of between about 0.5 mA and about 5 mA.
Clause 42. The method of any one of Clauses 35 to 41, wherein producing a positive charge includes delivering a current to the interventional element, the current having an amplitude of about 2 mA.
Clause 43. The method of any one of Clauses 35 to 42, wherein the interventional element comprises a thrombectomy device.
Clause 44. The method of any one of Clauses 35 to 43, wherein the interventional element comprises a stent retriever.
Clause 45. The method of any one of Clauses 35 to 44, wherein the interventional element comprises a removal device.
Clause 46. The method of any one of Clauses 35 to 45, wherein the interventional element is a laser-cut stent or a mesh.
Clause 47. A method, comprising:
Clause 48. The method of Clause 47, wherein an ion concentration of the fluid is greater than an ion concentration of blood.
Clause 49. The method of any one of Clauses 47 to 48, wherein the fluid is saline.
Clause 50. The method of any one of Clauses 47 to 48, wherein the fluid is contrast.
Clause 51. The method of any one of Clauses 47 to 50, wherein delivering the fluid to the treatment site increases an electrical conductivity at the treatment site.
Clause 52. The method of any one of Clauses 47 to 51, wherein delivering the fluid occurs while blood is flowing at the treatment site.
Clause 53. The method of any one of Clauses 47 to 51, wherein delivering the fluid occurs while blood flow is partially arrested at the treatment site.
Clause 54. The method of any one of Clauses 47 to 51, wherein delivering the fluid occurs while blood flow is completely arrested at the treatment site.
Clause 55. The method of any one of Clauses 47 to 54, further comprising expanding a flow arrest element within the blood vessel proximal of the treatment site before or while delivering the fluid.
Clause 56. The method of any one of Clauses 47 to 55, wherein the interventional element includes a first material and a second material disposed on the first material along at least a portion of the interventional element, wherein the second material is different than the first material.
Clause 57. The method of any one of Clauses 47 to 55, wherein the interventional element includes a first metallic material and a second metallic material disposed on the first metallic material along at least a portion of the interventional element, and wherein a conductivity of the second metallic material is greater than a conductivity of the first metallic material.
Clause 58. The method of Clause 57, wherein the second metallic material is gold.
Clause 59. The method of any one of Clauses 47 to 58, wherein applying a positive charge includes delivering an electric current to the interventional element from a power source positioned at an extracorporeal location.
Clause 60. The method of Clause 59, wherein the current is delivered while the interventional element is positioned at the treatment site.
Clause 61. The method of any one of Clauses 59 to 60, wherein the current has an amplitude of between about 0.5 mA and about 5 mA.
Clause 62. The method of any one of Clauses 59 to 61, wherein the current is a direct current.
Clause 63. The method of any one of Clauses 59 to 62, wherein the amplitude of the current remains generally constant.
Clause 64. The method of any one of Clauses 59 to 63, wherein the current is delivered for at least 30 seconds, at least 1 minute, or at least 2 minutes.
Clause 65. The method of any one of Clauses 47 to 64, wherein the interventional element comprises a thrombectomy device.
Clause 66. The method of any one of Clauses 47 to 65, wherein the interventional element comprises a stent retriever.
Clause 67. The method of any one of Clauses 47 to 66, wherein the interventional element comprises a removal device.
Clause 68. The method of any one of Clauses 47 to 67, wherein the interventional element is a mesh.
Clause 69. The method of any one of Clauses 47 to 68, wherein the interventional element is a laser-cut stent.
Clause 70. The method of any one of Clauses 47 to 69, wherein the fluid is delivered through a distal access catheter.
Clause 71. The method of any one of Clauses 47 to 70, wherein the fluid is a liquid.
Clause 72. A method, comprising:
Clause 73. The method of Clause 72, wherein an ion concentration of the fluid is greater than an ion concentration of blood.
Clause 74. The method of any one of Clauses 72 to 73, wherein the fluid is saline.
Clause 75. The method of any one of Clauses 72 to 73, wherein the fluid is contrast.
Clause 76. The method of any one of Clauses 72 to 74, wherein delivering the fluid occurs while blood is flowing at the treatment site.
Clause 77. The method of any one of Clauses 72 to 74, wherein delivering the fluid occurs while blood flow is partially arrested at the treatment site.
Clause 78. The method of any one of Clauses 72 to 74, wherein delivering the fluid occurs while blood flow is completely arrested at the treatment site.
Clause 79. The method of any one of Clauses 72 to 78, wherein delivering current to the thrombectomy device positively charges the thrombectomy device.
Clause 80. The method of any one of Clauses 72 to 79, wherein the thrombectomy device comprises a braid.
Clause 81. The method of any one of Clauses 72 to 80, wherein the thrombectomy device comprises a stent retriever.
Clause 82. The method of any one of Clauses 72 to 81, wherein the thrombectomy device comprises a removal device.
Clause 83. The method of any one of Clauses 72 to 82, wherein the thrombectomy device is a mesh.
Clause 84. The method of any one of Clauses 72 to 83, wherein the thrombectomy device is a laser-cut stent.
Clause 85. A thrombectomy system, comprising:
Clause 86. The system of Clause 85, wherein the electrode is in electrical communication with a conductive lead extending proximally along the catheter.
Clause 87. The system of Clause 86, wherein the conductive lead is disposed within a wall of the catheter.
Clause 88. The system of Clause 86, wherein the conductive lead is disposed along an external surface of the catheter.
Clause 89. The system of any one of Clauses 85 to 88, wherein the electrode comprises a conductive band extending at least partially circumferentially around the distal portion of the catheter.
Clause 90. The system of Clause 89, wherein the conductive band is disposed on an inner surface of the catheter.
Clause 91. The system of Clause 89, wherein the conductive band is disposed on an outer surface of the catheter.
Clause 92. The system of any one of Clauses 85 to 91, wherein the electrode comprises a stent engaged with an inner surface of the catheter.
Clause 93. The system of any one of Clauses 85 to 92, wherein the catheter comprises an aspiration catheter.
Clause 94. The system of any one of Clauses 85 to 93, wherein the catheter comprises a distal access catheter.
Clause 95. The system of any one of Clauses 85 to 93, wherein the catheter comprises a guide catheter.
Clause 96. The system of any one of Clauses 85 to 93, wherein the catheter comprises a balloon guide catheter.
Clause 97. The system of any one of Clauses 85 to 96, wherein the catheter is a first catheter and the system further comprises a second catheter, wherein the first catheter is configured to be slidably disposed within a lumen of the second catheter.
Clause 98. The system of any one of Clauses 85 to 96, wherein the catheter is a first catheter and the system further comprises a second catheter, wherein the second catheter is configured to be slidably disposed within a lumen of the first catheter.
Clause 99. The system of any one of Clauses 85 to 98, wherein the catheter is a microcatheter.
Clause 100. The system of any one of Clauses 85 to 96, wherein the catheter is a first catheter and the system further comprises a second catheter and a third catheter, wherein the first catheter is configured to be slidably disposed within a lumen of the second catheter, and the second catheter is configured to be slidably disposed within a lumen of the third catheter.
Clause 101. The system of any one of Clauses 85 to 100, wherein the electrode comprises a conductive band extending at least partially circumferentially around the distal portion of the catheter.
Clause 102. The system of Clause 101, wherein the conductive band is disposed on an inner surface of the catheter.
Clause 103. The system of Clause 101, wherein the conductive band is disposed on an outer surface of the catheter.
Clause 104. The system of any one of Clauses 85 to 103, further comprising a suction source configured to supply negative pressure through the catheter to aspirate a region adjacent to the distal portion of the catheter.
Clause 105. The system of any one of Clauses 85 to 104, wherein the catheter is an aspiration catheter having a proximal portion configured to be fluidically coupled to a suction source.
Clause 106. The system of any one of Clauses 85 to 105, further comprising a power supply having positive and negative terminals, the electrode being coupled to the negative terminal and the interventional element being coupled to the positive terminal.
Clause 107. The system of any one of Clauses 85 to 106, wherein, when the interventional element and the distal portion of the catheter are in the presence of an electrolytic medium and voltage is supplied to the first and second electrical terminals, current flows from the interventional element to the electrode.
Clause 108. The system of any one of Clauses 85 to 107, wherein a proximal end of the interventional element is coupled to a distal end of a core member, the core member extending proximally through the catheter.
Clause 109. The system of Clause 108, wherein the core member comprises an electrically conductive wire extending along its length.
Clause 110. The system of Clause 109, wherein the core member comprises an insulative coating surrounding the wire along at least a portion of its length.
Clause 111. The system of any one of Clauses 85 to 110, wherein the interventional element is electrically conductive.
Clause 112. The system of any one of Clauses 85 to 111, wherein the interventional element comprises a thrombectomy device.
Clause 113. The system of any one of Clauses 85 to 112, wherein the interventional element comprises a stent retriever.
Clause 114. The system of any one of Clauses 85 to 113, wherein the interventional element comprises a removal device.
Clause 115. The system of any one of Clauses 85 to 114, wherein the interventional element comprises a catheter.
Clause 116. The system of any one of Clauses 85 to 115, wherein a portion of the interventional element is coated with a conductive material.
Clause 117. The system of Clause 116, wherein the conductive material comprises gold.
Clause 118. The system of any one of Clauses 85 to 117, wherein a portion of the interventional element is coated with a non-conductive material.
Clause 119. The system of Clause 118, wherein the non-conductive material comprises parylene.
Clause 120. A medical device delivery system, comprising:
Clause 121. The system of Clause 120, wherein the shaft and the conductive lead are configured to be coupled to first and second terminals, respectively, of an extracorporeal power supply.
Clause 122. The system of any one of Clauses 120 to 121, wherein the shaft comprises a conductive element in electrical communication with the medical device
Clause 123. The system of any one of Clauses 120 to 122, wherein the medical device is electrically conductive.
Clause 124. The system of any one of Clauses 120 to 123, wherein the conductive lead is disposed within a wall of the tubular member.
Clause 125. The system of any one of Clauses 120 to 123, wherein the conductive lead is disposed along an external surface of the tubular member.
Clause 126. The system of any one of Clauses 120 to 125, wherein the electrode comprises a conductive band extending at least partially circumferentially around the distal portion of the tubular member.
Clause 127. The system of Clause 126, wherein the conductive band is disposed on an inner surface of the tubular member.
Clause 128. The system of Clause 126, wherein the conductive band is disposed on an outer surface of the tubular member.
Clause 129. The system of any one of Clauses 120 to 128, wherein the electrode comprises a stent engaged with an inner surface of the tubular member.
Clause 130. The system of any one of Clauses 120 to 129, wherein the tubular member comprises an aspiration catheter.
Clause 131. The system of any one of Clauses 120 to 129, wherein the tubular member comprises a guide catheter.
Clause 132. The system of any one of Clauses 120 to 131, further comprising a suction source configured to supply negative pressure through the tubular member to aspirate a region adjacent to a distal portion of the tubular member.
Clause 133. The system of any one of Clauses 120 to 132, wherein the tubular member is an aspiration catheter having a proximal portion configured to be fluidically coupled to a suction source.
Clause 134. The system of any one of Clauses 120 to 133, further comprising a power supply having positive and negative terminals, the electrode being coupled to the negative terminal and the shaft being coupled to the positive terminal.
Clause 135. The system of Clause 134, wherein, when the medical device and the distal portion of the tubular member are in the presence of an electrolytic medium and voltage is supplied to the positive and negative terminals, current flows from the medical device the electrode.
Clause 136. The system of any one of Clauses 120 to 135, wherein the shaft comprises an electrically conductive wire extending along its length.
Clause 137. The system of Clause 136, wherein the shaft comprises an insulative coating surrounding the wire along at least a portion of its length.
Clause 138. The system of any one of Clauses 120 to 137, wherein the medical device comprises a thrombectomy device.
Clause 139. The system of any one of Clauses 120 to 138, wherein the medical device comprises a stent retriever.
Clause 140. The system of any one of Clauses 120 to 139, wherein the medical device comprises a removal device.
Clause 141. The system of any one of Clauses 120 to 140, wherein the medical device comprises a catheter.
Clause 142. The system of any one of Clauses 120 to 141, wherein a portion of the medical device is coated with a conductive material.
Clause 143. The system of Clause 142, wherein the conductive material comprises gold.
Clause 144. The system of any one of Clauses 120 to 143, wherein a portion of the medical device is coated with a non-conductive material.
Clause 145. The system of Clause 144, wherein the non-conductive material comprises parylene.
Clause 146. A method, comprising:
Clause 147. The method of Clause 146, further comprising ceasing the supplying of electric current to the second electrical terminal after a first time period.
Clause 148. The method of Clause 147, further comprising, after ceasing the supplying of electric current, proximally retracting the core member with respect to the catheter.
Clause 149. The method of any one of Clauses 147 to 148, wherein the first time period is less than about 5 minutes.
Clause 150. The method of any one of Clauses 147 to 149, wherein the first time period is less than about 2 minutes.
Clause 151. The method of any one of Clauses 146 to 150, wherein the electrode is coupled to the first electrical terminal via a conductive lead extending proximally along the catheter.
Clause 152. The method of Clause 151, wherein the conductive lead is disposed within a wall of the catheter.
Clause 153. The method of Clause 151, wherein the conductive lead is disposed along an external surface of the catheter.
Clause 154. The method of any one of Clauses 146 to 153, wherein the electrode comprises a conductive band extending at least partially circumferentially around the distal portion of the catheter.
Clause 155. The method of Clause 154, wherein the conductive band is disposed on an inner surface of the catheter.
Clause 156. The method of Clause 154, wherein the conductive band is disposed on an outer surface of the catheter.
Clause 157. The method of any one of Clauses 146 to 156, wherein the electrode comprises a stent engaged with an inner surface of the catheter.
Clause 158. The method of any one of Clauses 146 to 157, further comprising supplying negative pressure through the catheter to aspirate a region adjacent to the treatment site.
Clause 159. The method of any one of Clauses 146 to 158, wherein the treatment site in the body is proximate to or adjacent to a thrombus in a blood vessel.
Clause 160. The method of any one of Clauses 146 to 159, further comprising, after advancing the interventional element through the catheter, expanding the interventional element adjacent to a thrombus in a blood vessel.
Clause 161. The method of any one of Clauses 146 to 160, wherein the interventional element comprises a thrombectomy device.
Clause 162. The method of any one of Clauses 146 to 161, wherein the interventional element comprises a stent retriever.
Clause 163. The method of any one of Clauses 146 to 162, wherein the interventional element comprises a removal device.
Clause 164. The method of any one of Clauses 146 to 163, wherein the interventional element is coupled to the second electrical terminal of the power supply via a conductive pushwire.
Clause 165. The method of any one of Clauses 146 to 164, further comprising:
Clause 166. The method of Clause 165, further comprising:
Clause 167. The method of any one of Clauses 165 to 166, wherein arresting the blood flow comprises expanding a balloon of a balloon-guide catheter at a position proximal to the treatment site.
Clause 168. An aspiration device, comprising:
Clause 169. The device of Clause 168, wherein the electrode comprises a conductive band extending at least partially circumferentially around the distal portion of the catheter.
Clause 170. The device of Clause 169, wherein the conductive band is disposed on an inner surface of the catheter.
Clause 171. The device of any one of Clauses 168 to 170, wherein the conductive lead comprises a wire disposed within a wall of the catheter.
Clause 172. The device of any one of Clauses 168 to 170, wherein the conductive lead comprises a wire disposed around an external surface of the catheter.
Clause 173. The device of any one of Clauses 168 to 172, further comprising:
Clause 174. The device of Clause 173, wherein the second electrode comprises a conductive band disposed at the distal portion of the catheter, and wherein the second conductive lead comprises a wire disposed within a wall of the catheter.
Clause 175. The device of Clause 173, wherein the second electrode comprises a conductive band disposed at the distal portion of the catheter, and wherein the second conductive lead comprises a wire disposed around an external surface of the catheter.
Clause 176. The device of Clause 173, wherein the second electrode comprises a flow-arrest element coupled to the distal portion of the catheter.
Clause 177. The device of Clause 173, wherein the second electrode is physically separate from the catheter.
Clause 178. The device of Clause 177, wherein the second electrode comprises a needle.
Clause 179. The device of Clause 177, wherein the second electrode comprises a grounding pad.
Clause 180. The device of any one of Clauses 168 to 179, further comprising a suction source configured to supply negative pressure through the catheter to aspirate a region adjacent to the distal portion of the catheter.
Clause 181. The device of any one of Clauses 168 to 180, further comprising a power supply having positive and negative terminals, the conductive lead being coupled to the positive terminal and a return electrode being coupled to the negative terminal.
Clause 182. A method, comprising:
Clause 183. The method of Clause 182, further comprising disposing a second electrode at a position spaced apart from the first electrode, the second electrode coupled to a second electrical terminal of the power supply.
Clause 184. The method of Clause 183, wherein the first electrical terminal is positive, and wherein the second electrical terminal is negative.
Clause 185. The method of any one of Clauses 183 to 184, wherein the second electrode comprises a needle.
Clause 186. The method of any one of Clauses 183 to 184, wherein the second electrode comprises a grounding pad.
Clause 187. The method of any one of Clauses 183 to 184, wherein the second electrode comprises a conductive element disposed in the distal portion of the catheter.
Clause 188. The method of any one of Clauses 182 to 187, further comprising supplying the electric current to the first electrical terminal while supplying the negative pressure through the catheter.
Clause 189. The method of any one of Clauses 182 to 188, further comprising ceasing the supplying of electric current to the first electrical terminal after a first time period.
Clause 190. The method of Clause 189, wherein the first time period is less than about 5 minutes.
Clause 191. The method of Clause 189, wherein the first time period is less than about 2 minutes.
Clause 192. The method of any one of Clauses 182 to 191, wherein the first electrode is coupled to the first electrical terminal via a conductive lead extending proximally along the catheter.
Clause 193. The method of Clause 192, wherein the conductive lead is disposed within a wall of the catheter.
Clause 194. The method of Clause 192, wherein the conductive lead is disposed along an external surface of the catheter.
Clause 195. The method of Clause 182 to 194, wherein the first electrode comprises a conductive band extending at least partially circumferentially around the distal portion of the catheter.
Clause 196. The method of Clause 195, wherein the conductive band is disposed on an inner surface of the catheter.
Clause 197. The method of Clause 195, wherein the conductive band is disposed on an outer surface of the catheter.
Clause 198. The method of any one of Clauses 182 to 197, wherein the first electrode comprises a stent engaged with an inner surface of the catheter.
Clause 199. The method of any one of Clauses 182 to 198, wherein the treatment site in the body is proximate to or adjacent to a thrombus in a blood vessel.
Additional features and advantages of the present technology are described below, and in part will be apparent from the description, or may be learned by practice of the present technology. The advantages of the present technology will be realized and attained by the structure particularly pointed out in the written description and claims hereof as well as the appended drawings.
Many aspects of the present technology can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale. Instead, emphasis is placed on illustrating clearly the principles of the present disclosure.
The present technology provides devices, systems, and methods for removing clot material from a blood vessel lumen. Although many of the embodiments are described below with respect to devices, systems, and methods for treating a cerebral or intracranial embolism, other applications and other embodiments in addition to those described herein are within the scope of the technology. For example, the treatment systems and methods of the present technology may be used to remove emboli from body lumens other than blood vessels (e.g., the digestive tract, etc.) and/or may be used to remove emboli from blood vessels outside of the brain (e.g., pulmonary, abdominal, cervical, or thoracic blood vessels, or peripheral blood vessels including those within the legs or arms, etc.). In addition, the treatment systems and methods of the present technology may be used to remove luminal obstructions other than clot material (e.g., plaque, resected tissue, foreign material, etc.).
In some embodiments, the treatment system 10 includes a suction source 25 (e.g., a syringe, a pump, etc.) configured to be fluidly coupled (e.g., via a connector 23) to a proximal portion of one or more of the first catheter 14, the second catheter 13, and/or the third catheter 12 to apply negative pressure therethrough. In some embodiments, the treatment system 10 includes a fluid source 27 (e.g., a fluid reservoir, a syringe, pump, etc.) configured to be fluidly coupled (e.g., via the connector 23) to a proximal portion of one or more of the first catheter 14, the second catheter 13, and/or the third catheter 12 to supply fluid (e.g., saline, contrast agents, a drug such as a thrombolytic agent, etc.) to the treatment site.
According to some embodiments, the current generator 20 can include an electrical generator configured to output medically useful electric current.
As noted above, the current generator 20 may be coupled to a proximal portion of the core member 11, and/or a proximal portion of the third catheter 12, the second catheter 13, and/or first catheter 14 to provide an electric current to the interventional element 100. For example, in some embodiments, both terminals of the current generator 20 are coupled to the core member 11 such that the core member 11 functions as both a delivery electrode or conductive path (i.e., transmitting current from the current generator 20 to the treatment site) and a return electrode or conductive path (i.e., transmitting current from the treatment site to the current generator 20) (described in greater detail below with reference to
As noted above, the interventional element 100 can serve as the delivery electrode and be electrically coupled to a positive terminal of the current generator 20 (
The return electrode(s) can assume a variety of configurations in different embodiments. For example, in some embodiments, the return electrode is an external electrode 29 (
According to some embodiments, for example as shown in
The second catheter 13 can be sized and configured to be slidably receive the third catheter 12 therethrough. As noted above, the second catheter 13 can be coupled at a proximal portion to a suction source 25 (
According to some embodiments, the bodies of the catheters 12, 13, and 14 can be made from various thermoplastics, e.g., polytetrafluoroethylene (PTFE or TEFLON®), fluorinated ethylene propylene (FEP), high-density polyethylene (HDPE), polyether ether ketone (PEEK), etc., which can optionally be lined on the inner surface of the catheters or an adjacent surface with a hydrophilic material such as polyvinylpyrrolidone (PVP) or some other plastic coating. Additionally, either surface can be coated with various combinations of different materials, depending upon the desired results.
According to some embodiments, an electrode 204 is provided at a distal end region of the third catheter 12. The electrode 204 can form an annular ring that extends entirely circumferentially about the central axis of the third catheter 12. Alternatively or in combination, the electrode 204 can extend less than entirely circumferentially around the third catheter 12. For example, the electrode 204 may be entirely disposed on one radial side of the central axis. By further example, the electrode 204 may provide a plurality of discrete, noncontiguous electrode sections about the central axis. Such sections of the electrode 204 can be in electrical communication with a common conductive path so as to function collectively as a single electrode, or with multiple separate such paths to allow the sections to function independently if desired. The electrode 201 can be a band, a wire, or a coil embedded in the wall of the third catheter 12. According to some embodiments, the electrode 204 can be longitudinally separated from the distal end 201 of the third catheter 12 by a non-conductive portion of the third catheter 12. Alternatively, a distal portion of the electrode 204 can extend to the distal end 201 of the third catheter 12, such that the electrode 204 forms a portion of the distal end 201. According to some embodiments, an inner surface of the electrode 204 can be flush with an inner surface of the third catheter 12. Alternatively or in combination, the inner surface of the electrode 204 can extend more radially inwardly relative to the inner surface of the third catheter 12 (e.g., providing a “step”). Alternatively or in combination, the inner surface of the electrode 204 can extend less radially inwardly relative to the inner surface of the third catheter 12 (e.g., be recessed into the body). According to some embodiments, the electrode 201 can be surrounded radially by an outer section of the third catheter 12 to provide insulation from an external environment. In some embodiments, an outer surface of the electrode 204 can be flush with an outer surface of the third catheter 12 and can provide an exposed, radially outwardly facing electrode surface. In such instances, a radially inner section of the third catheter 12 can provide insulation from the environment within the lumen of the third catheter 12.
The electrode 204 can include one or more rings, one or more coils or other suitable conductive structures, and can each form at least one surface (e.g., an inner surface or an outer surface) that is exposed and configured for electrical activity or conduction. The electrode 204 can have a fixed inner diameter or size, or a radially expandable inner diameter or size. In some embodiments, the electrode 204 is a “painted” electrode. The electrode can include platinum, platinum alloys (e.g., 92% platinum and 8% tungsten, 90% platinum and 10% iridium), gold, cobalt-chromium, stainless steel (e.g., 304 or 316), nitinol, and combinations thereof, or any suitable conductive materials, metals or alloys.
In some embodiments, the electrode 204 can be a separate expandable member coupled to an outer surface of the third catheter 12, for example a braid, stent, or other conductive element coupled to an outer surface of the distal portion of the third catheter 12. In some embodiments, the electrode can be part of a flow-arrest element such as an expandable braid coupled to an occlusion balloon.
According to some embodiments, the electrode 204 can be electrically connected to the current generator 20 via a conductive lead 205. The conductive lead 205 can extend proximally along or within the wall of the third catheter 12 to or beyond the proximal end of the third catheter 12. The conductive lead 205 can include more than one conductive path extending within the walls of the third catheter 12. According to some embodiments, the conductive lead 205 can form a helical coil along or within at least a portion of the third catheter 12. Alternatively or in combination, the conductive lead 205 can form a braided, woven, or lattice structure along or within at least a portion of the third catheter 12. In some embodiments, the conductive lead 205 can be a conductive element (e.g., a wire, coil, etc.) wrapped around an external surface of the third catheter 12. In such instances, the conductive lead 205 can be coated with an insulative material along at least a portion of its length. The insulative material can be, for example, Parylene, PTFE, or other suitable insulative material.
In some embodiments, the second catheter 13 and/or the first catheter 14 can be similarly equipped with corresponding electrodes instead of or in addition to the third catheter 12 or the core member 11. For example, the second catheter 13 may include an electrode 206 disposed at a distal end region of the second catheter 13. The electrode 206 can be electrically connected to the current generator 20 (
In some embodiments, the first catheter 14 includes an electrode 208 disposed at a distal end region of the first catheter 14. The electrode 208 can be electrically connected to the current generator 20 (
In various embodiments, the system can include any combination of the electrodes 204, 206, and 208 described above. For example, the system may include the electrode 204 and the corresponding conductive lead 205 of the third catheter 12, while the second catheter 13 and the first catheter 14 may be provided with no electrodes or conductive leads therein. In other embodiments, the system may only include the electrode 206 of the second catheter 13, while the third catheter 12 and the first catheter 14 may be provided with no electrodes or conductive leads therein. In still other embodiments, the system may include only the electrode 208 of the first catheter 14, while the third catheter 12 and the second catheter 13 are provided with no electrodes or corresponding conductive leads therein. In some embodiments, any two of the catheters 12, 13, or 14 can be provided with electrodes and corresponding leads, while the remaining catheter may have no electrode or conductive lead therein.
In the configuration illustrated in
In some embodiments, one or more catheters carrying an electrode can be used without an electrically coupled interventional element 100. In various embodiments, the interventional element 100 may be omitted altogether (as in
As described in more detail in
In some embodiments, the shaft 211 can be a solid pushwire, for example a wire made of Nitinol, stainless steel, or other metal or alloy. The shaft 211 may be thinner than would otherwise be required due to the additional structural column strength provided by the surrounding tubular member 212. The tubular member 212 can be a hollow wire, hypotube, braid, coil, or other suitable member(s), or a combination of wire(s), tube(s), braid(s), coil(s), etc. In some embodiments, the tubular member 212 can be a laser-cut hypotube having a spiral cut pattern (or other pattern of cut voids) formed in its sidewall along at least a portion of its length. The tubular member 212 can be made of stainless steel (e.g., 304 SS), Nitinol, and/or other alloy. In at least some embodiments, the tubular member 212 can have a laser cut pattern to achieve the desired mechanical characteristics (e.g., column strength, flexibility, kink-resistance, etc.).
The core member 11 can also include an adhesive or a mechanical coupler such as a crimped band or marker band 220 disposed at the distal end of the core member 11, and the marker band 220 can optionally couple the distal end of the core member 11 to the interventional element 100. The marker band 220 can be radiopaque, for example including platinum or other radiopaque material, thereby enabling visualization of the proximal end of the interventional element 100 under fluoroscopy. In some embodiments, additional radiopaque markers can be disposed at various locations along the treatment system 10, for example along the shaft 211, the tubular member 212, or the interventional element 100 (e.g., at the distal end, or along the length, of the interventional element 100).
In at least some embodiments, the core member 11 also includes a first insulating layer or material 222 extending between the shaft 211 and the surrounding tubular member 212. The first insulating material 222 can be, for example, PTFE (polytetrafluoroethylene or TEFLON™) or any other suitable electrically insulating coating (e.g., polyimide, oxide, ETFE-based coatings, or any suitable dielectric polymer). In some embodiments, the first insulating material 222 extends along substantially the entire length of the shaft 211. In some embodiments, the first insulating material 222 separates and electrically insulates the shaft 211 and the tubular member 212 along the entire length of the tubular member 212. In some embodiments, the first insulating material 222 does not cover the proximal-most portion of the shaft 211, providing an exposed region of the shaft to which the current generator 20 (
The core member 11 can additionally include a second insulating layer or material 224 surrounding the tubular member 212 along at least a portion of its length. The second insulating layer 224 can be, for example, PTFE or any other suitable electrically insulative coating (e.g., polyimide, oxide, ETFE based coatings or any suitable dielectric polymer). In some embodiments, the distal portion 218 of the tubular member 212 is not covered by the second insulating layer 224, leaving an exposed conductive surface at the distal portion 218. In some embodiments, the length of the exposed distal portion 218 of the tubular member 212 can be at least (or equal to) 1, 2, 3, 4, 5, 6, or more inches. In some embodiments, the length of the exposed distal portion 218 of the tubular member 212 can be between at least 1 and 10 inches, or between 2 inches and 8 inches, or between 3 and 7 inches, or between 4 and 6 inches, or about 5 inches. This exposed portion of the distal portion 218 of the tubular member 212 provides a return path for current supplied to the delivery electrode (e.g. the entirety or a portion of the interventional element 100), as described in more detail below. In some embodiments, the second insulating material 224 does not cover the proximal-most portion of the tubular member 212, providing an exposed region of the tubular member 212 to which the current generator 20 (
The core member 11 can also include a retraction marker in the proximal portion of the tubular member 212. The retraction marker can be a visible indicator to guide a clinician when proximally retracting an overlying catheter with respect to the core member 11. For example, the retraction marker can be positioned such that when a proximal end of the overlying catheter is retracted to be positioned at or near the retraction marker, the distal portion 218 of the tubular member 212 is positioned distally beyond a distal end of the catheter. In this position, the exposed distal portion 218 of the tubular member 212 is exposed to the surrounding environment (e.g., blood, tissue, etc.), and can serve as a return electrode for the core member 11.
The proximal end of the shaft 211 can be electrically coupled to the positive terminal of the current generator 20, and the proximal end of the tubular member 212 can be electrically coupled to the negative terminal of the current generator 20. During operation, the treatment system 10 provides an electrical circuit in which current flows from the positive terminal of the current generator 20, distally through the shaft 211, the interventional element 100, and the surrounding media (e.g., blood, tissue, thrombus, etc.) before returning back to the exposed distal portion 218 of the tubular member, proximally through the tubular member 212, and back to the negative terminal of the current generator 20 (
As noted above, the current generator 20 (
In certain embodiments, the polarities of the current generator 20 can be switched, so that the negative terminal is electrically coupled to the shaft 211 and the positive terminal is electrically coupled to the tubular member 212. This can be advantageous when, for example, attempting to attract predominantly positively charged material to the interventional element 100, or when attempting to break up a clot rather than grasp it with an interventional element. In some embodiments alternating current (AC) signals may be used rather than DC. In certain instances, AC signals may advantageously help break apart a thrombus or other material.
Referring still to
In various embodiments, the interventional element 100 can take any number of forms, for example a removal device, a thrombectomy device, or other suitable medical device. For example, in some embodiments the interventional element 100 may be a stent and/or stent retriever, such as Medtronic's Solitaire™ Revascularization Device, Stryker Neurovascular's Trevo® ProVue™ Stentriever, or other suitable devices. In some embodiments, the interventional element 100 may be a coiled wire, a weave, and/or a braid formed of a plurality of braided filaments. Examples of suitable interventional elements 100 include any of those disclosed in U.S. Pat. No. 7,300,458, filed Nov. 5, 2007, U.S. Pat. No. 8,940,003, filed Nov. 22, 2010, U.S. Pat. No. 9,039,749, filed Oct. 1, 2010, and U.S. Pat. No. 8,066,757, filed Dec. 28, 2010, each of which is incorporated by reference herein in its entirety.
In some embodiments, the interventional element 100 is a mesh structure (e.g., a braid, a stent, etc.) formed of a superelastic material (e.g., Nitinol) or other resilient or self-expanding material configured to self-expand when released from the third catheter 12. The mesh structure may include a plurality of struts 101 and open spaces 103 between the struts 101. In some embodiments, the struts 101 and spaces 103 may be situated along the longitudinal direction of the interventional element 100, the radial direction, or both.
As depicted in
In some embodiments, the non-working length NWL portion of the interventional element 100 can be coated with a non-conductive or insulative material (e.g., Parylene, PTFE, or other suitable non-conductive coating) such that the coated region is not in electrical contact with the surrounding media (e.g., blood). As a result, the current carried by the core member 11 to the interventional element 100 is only exposed to the surrounding media along the working length WL portion of the interventional element 100. This can advantageously concentrate the electrically enhanced attachment effect along the working length WL of the interventional element 100, where it is most useful, and thereby combine both the mechanical interlocking provided by the working length WL and the electrical enhancement provided by the delivered electrical signal. In some embodiments, a distal region of the interventional element 100 (e.g. distal of the working length WL) may likewise be coated with a non-conductive material (e.g., Parylene, PTFE, or other suitable non-conductive coating), leaving only a central portion or the working length WL of the interventional element 100 having an exposed conductive surface.
In some embodiments, the interventional element 100 may include a conductive material positioned on some or all of its outer surface. The conductive material, for example, can be gold and/or another suitable conductor that has a conductivity greater than (or a resistivity less than) that of the material comprising the interventional element 100. The conductive material may be applied to the interventional element 100 via electrochemical deposition, sputtering, vapor deposition, dip-coating, and/or other suitable means.
As shown in
In some aspects of the present technology, the conductive material 301 is disposed only on the working length WL portion of the interventional element 100 such that the proximal and distal portions 100a, 100b of the interventional element 100 are exposed. Because the conductive material 301 has a much lower resistance than the underlying material comprising the interventional element 100, current delivered to the interventional element 100 concentrates along the working length WL portion. In several of such embodiments, the conductive material 301 may be disposed only on the outer portion 101a of the strut surface along the working length WL portion. In other embodiments, the conductive material 301 may be disposed on all or a portion of the strut surface along all or a portion of the length of the interventional element 100.
In some embodiments, a first portion of the interventional element 100 is covered by the conductive material 301 and a second portion of the interventional element 100 is covered by an insulative or dielectric material (e.g., Parylene). For example, in some embodiments the outer portion 101a of the strut surface is covered by a conductive material while an inner portion 101c of the strut surface is covered by an insulative material. In some embodiments, the working length WL portion of the interventional element 100 may be covered by a conductive material while the non-working length NWL portion is covered by an insulative material. In some embodiments, the conductive material 301 may be disposed on all or a portion of the strut surface along all or a portion of the length of the interventional element 100, and the insulative material may be disposed on those portions of the strut surface and/or working length not covered by the conductive material.
As shown in
Once the interventional element 100 has been expanded into engagement with the clot material CM, the interventional element 100 may grip the clot material CM by virtue of its ability to mechanically interlock with the clot material CM. The current generator 20, which is electrically coupled to the proximal end of the core member 11, can deliver a current to the interventional element 100 before or after the interventional element 100 has been released from the third catheter 12 into the blood vessel and/or expanded into the clot material CM. The interventional element 100 can be left in place or manipulated within the vessel V for a desired time period while the electrical signal is being delivered. Positive current delivered to the interventional element 100 can attract negatively charged constituents of the clot material CM, thereby enhancing the grip of the interventional element 100 on the clot material CM. This allows the interventional element 100 to be used to retrieve the clot material CM with reduced risk of losing grip on the thrombus or a piece thereof, which can migrate downstream and cause additional vessel blockages in areas of the brain that are more difficult to reach.
In some methods of the present technology, a guidewire (not shown) may be advanced to the treatment site and pushed through the clot material CM until a distal portion of the guidewire is distal of the clot material CM. The guidewire may be advanced through one or more of the catheters 12-14 and/or one or more of the catheters 12-14 may be advanced over the guidewire. The guidewire may be insulated along at least a portion of its length (e.g., with parylene, PTFE, etc.), with exposed portions permitting electrical communication with the current generator 20 and the interventional element 100. For example, in some embodiments a distal portion of the guidewire may be exposed and the guidewire may be positioned at the treatment site such that the exposed portion of the guidewire is distal of the clot material CM. A proximal end of the guidewire may be coupled to the current generator such that the exposed portion of the guidewire functions as a return electrode. In some embodiments, the guidewire may be coupled to the positive terminal of the power source and the exposed portion functions as a delivery electrode. The guidewire may be used as a delivery or return electrode with any delivery or return electrode carried by any component of the treatment system (e.g., one or more of the first-third catheters 14, 13, 12, the interventional element 100, etc.).
Although the presence of blood flow at the treatment site is believed to reduce adhesion between an electrically charged interventional element and a blood clot, the inventors have also observed that infusion of a fluid F having a higher ion concentration than blood increases the electrical conductivity at the treatment site, thereby providing an improved environment for electrically enhanced clot adhesion as compared to the presence of blood alone. The same experimental setup described above was used and the blood was replaced by saline with flow at 150 mL/min. The inventors observed that the adhesive force was approximately 35% higher when saline was infused at the treatment site than it was in the presence of autologous blood alone. In some embodiments, infusion of the fluid F may occur in the presence of blood flow, or without blood flow present (the latter condition being induced, for example, by inflation of the expandable element 401 on the first catheter 14). Suitable fluids include, for example, saline, contrast solution, and other fluids having a higher ion concentration than blood. Additionally, the delivery of fluid F at the treatment site may also reduce new clot formation on the interventional element 100, which may occur in the presence of blood and direct or pulsatile electric current.
Referring now to
In some embodiments, aspiration is applied while the interventional element 100 is retracted into the second catheter 13. Aspiration at this stage can help secure the clot material CM within the second catheter 13 and prevent any dislodged portion of the clot material CM from escaping the second catheter 13 and being released back into the vessel V. In various embodiments, the treatment site can be aspirated continuously before, during, or after delivering electrical signals to the interventional element 100 as well as before, during, or after retraction of the interventional element 100 into the second catheter 13.
With reference to
In some methods, the flow arrest element may be deployed at a location along the blood vessel proximal of the clot material CM (for example, at a proximal portion of the internal carotid artery) and may remain inflated as the interventional element 100 is deployed and eventually withdrawn to remove the thrombus. For example,
As shown in
At least while the interventional element 100 is deployed and engaging the thrombus CM, electric current may be delivered to the interventional element 100 to positively charge the interventional element 100, thereby enhancing clot adhesion to the interventional element 100. As previously discussed with reference to
With reference to
While in the position shown in
The negative terminal of the current generator 20 can be coupled to a return electrode to complete the electrical circuit with the first electrode disposed on the catheter 603. In some embodiments, the return electrode can be an external electrode (e.g., a needle or a grounding pad coupled to the patient's skin). In other embodiments, the return electrode can be carried by a separate catheter, for example the electrode 208 of the catheter 604 shown in
When the first and second electrodes are coupled to the positive and negative terminals, respectively, of the current generator 20, the distal end of the catheter 603 becomes positively charged and attracts negatively charged constituents in the blood and clot material CM. This electrical attraction promotes movement of the clot material CM into the catheter 603, adhesion of the clot material CM to the inner surface of the catheter 603, and retention of the clot material CM in the lumen of the catheter 603.
In various embodiments, aspiration can be performed via the catheter 603 before, during, and/or after supplying electrical energy to the first electrode via the current generator 20. In some embodiments, the electrical signals can continue to be applied while the catheter 603 and attached clot material CM are retracted proximally through the vessel V towards the catheter 604. In some embodiments, the current generator 20 can cease to supply electrical signals to the first electrode, while negative pressure can continue to be supplied to the catheter 603.
In
While applying a continuous uniform direct current (DC) electrical signal (as shown in
The waveform shape (e.g., pulse width, duty cycle, amplitude) and length of time can each be selected to achieve desired power delivery parameters, such as overall electrical charge, total energy, and peak current delivered to the interventional element and/or catheter. In some embodiments, the overall electrical charge delivered to the interventional element and/or catheter can be between about 30-1200 mC, or between about 120-600 mC. According to some embodiments, the total electrical charge delivered to the interventional element and/or catheter may be less than 600 mC, less than 500 mC, less than 400 mC, less than 300 mC, less than 200 mC, or less than 100 mC.
In some embodiments, the total energy delivered to the interventional element and/or aspiration catheter can be between about 0.75-24,000 mJ, or between about 120-24,000 mJ, or between about 120-5000 mJ. According to some embodiments, the total energy delivered to the interventional element and/or aspiration catheter may be less than 24,000 mJ, less than 20,000 mJ, less than 15,000 mJ, less than 10,000 mJ, less than 5,000 mJ, less than 4,000 mJ, less than 3,000 mJ, less than 2000 mJ, less than 1,000 mJ, less than 900 mJ, less than 800 mJ, less than 700 mJ, less than 600 mJ, less than 500 mJ, less than 400 mJ, less than 300 mJ, or less than 200 mJ, or less than 120 mJ, or less than 60 mJ, or less than 48 mJ, or less than 30 mJ, or less than 12 mJ, or less than 6 mJ, or less than 1.5 mJ.
In some embodiments, the peak current delivered can be between about 0.5-20 mA, or between about 0.5-5 mA. According to some embodiments, the peak current delivered may be greater than 0.5 mA, greater than 1 mA, greater than 1.5 mA, greater than 2 mA, greater than 2.5 mA, or greater than 3 mA.
The duration of power delivery is another important parameter that can be controlled to achieve the desired clot-adhesion effects without damaging tissue at the treatment site or generating new clots. In at least some embodiments, the total energy delivery time can be no more than 1 minute, no more than 2 minutes, no more than 3 minutes, no more than 4 minutes, or no more than 5 minutes. According to some embodiments, the total energy delivery time may be less about 30 seconds, less than about 1 minute, less than about 90 seconds, or less than about 2 minutes. As used herein, the “total energy delivery time” refers to the time period during which the waveform is supplied to the interventional element and/or catheter (including those periods of time between pulses of current).
The duty cycle of the applied electrical signal can also be selected to achieve the desired clot-adhesion characteristics without ablating tissue or promoting new clot formation. In some embodiments, the duty cycle can be between about 5% about 99% or between about 5% to about 20%. According to some embodiments, the duty cycle may be about 10%, about 20%, about 30%, about 40%, or about 50%. In yet other embodiments, a constant current may be used, in which the duty cycle is 100%. For 100% duty cycle embodiments, a lower time or current may be used to avoid delivering excess total energy to the treatment site.
Table 1 presents a range of values for power delivery parameters of different waveforms. For each of the conditions set forth in Table 1, a resistance of 1 kohm and a frequency of 1 kHz (for the Square, Triangle, and Composite conditions) was used. The Constant conditions represent a continuous and steady current applied for the duration, i.e. 100% duty cycle. The Peak Current 1 column represents the peak current for the corresponding waveform. For the Composite conditions, the Peak Current 2 column indicates the peak current of the second portion of the waveform. For example, referring back to
As seen in Table 1, the periodic waveforms (Square, Triangle, and Composite conditions) achieve higher peak currents with lower overall charge delivered than the corresponding Constant conditions. For example, in condition Constant 4, a peak current of 20 mA corresponds to a total energy delivered of 24,000 mJ, while condition Square 3 delivers a peak current of 20 mA with a total energy of only 4,800 mJ. Conditions Triangle 2 and Composite 1 similarly deliver lower total energy while maintaining a peak current of 20 mA. Since clot-adhesion appears to be driven by peak current, these periodic waveforms can therefore offer improved clot adhesion while reducing the risk of damaging tissue at the treatment site or promoting new clot formation. Table 1 also indicates that the Triangle and Composite conditions achieve higher peak currents with lower overall charge delivered than the corresponding Square conditions. For example, condition Square 3 has a peak current of 20 mA and a total charge delivered of 240 mC, while condition Triangle 2 has a peak current of 20 mA but a total charge delivered of only 120 mC, and condition Composite 1 has a peak current of 20 mA and a total charge delivered of only 144 mC. As such, these non-square waveforms provide additional benefits by delivering desirable peak current while reducing the overall charge delivered to the treatment site.
Although Table 1 represents a series of waveforms with a single frequency (1 kHz), in some embodiments the frequency of the pulsed-DC waveforms can be controlled to achieve the desired effects. For example, in some embodiments the frequency of the waveform can be between 1 Hz and 1 MHz, between 1 Hz and 1 kHz, or between 500 Hz to 1 kHz.
This disclosure is not intended to be exhaustive or to limit the present technology to the precise forms disclosed herein. Although specific embodiments are disclosed herein for illustrative purposes, various equivalent modifications are possible without deviating from the present technology, as those of ordinary skill in the relevant art will recognize. In some cases, well-known structures and functions have not been shown and/or described in detail to avoid unnecessarily obscuring the description of the embodiments of the present technology. Although steps of methods may be presented herein in a particular order, in alternative embodiments the steps may have another suitable order. Similarly, certain aspects of the present technology disclosed in the context of particular embodiments can be combined or eliminated in other embodiments. Furthermore, while advantages associated with certain embodiments may have been disclosed in the context of those embodiments, other embodiments can also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages or other advantages disclosed herein to fall within the scope of the present technology. Accordingly, this disclosure and associated technology can encompass other embodiments not expressly shown and/or described herein.
Throughout this disclosure, the singular terms “a,” “an,” and “the” include plural referents unless the context clearly indicates otherwise. Similarly, unless the word “or” is expressly limited to mean only a single item exclusive from the other items in reference to a list of two or more items, then the use of “or” in such a list is to be interpreted as including (a) any single item in the list, (b) all of the items in the list, or (c) any combination of the items in the list. Additionally, the terms “comprising” and the like are used throughout this disclosure to mean including at least the recited feature(s) such that any greater number of the same feature(s) and/or one or more additional types of features are not precluded. Directional terms, such as “upper,” “lower,” “front,” “back,” “vertical,” and “horizontal,” may be used herein to express and clarify the relationship between various elements. It should be understood that such terms do not denote absolute orientation. Reference herein to “one embodiment,” “an embodiment,” or similar formulations means that a particular feature, structure, operation, or characteristic described in connection with the embodiment can be included in at least one embodiment of the present technology. Thus, the appearances of such phrases or formulations herein are not necessarily all referring to the same embodiment. Furthermore, various particular features, structures, operations, or characteristics may be combined in any suitable manner in one or more embodiments.
The present application is a continuation of U.S. patent application Ser. No. 17/303,208, filed May 24, 2021, which is a divisional of U.S. patent application Ser. No. 16/024,408, filed Jun. 29, 2018, now issued as U.S. Pat. No. 11,090,071, which claims the benefit of priority to U.S. Provisional Application No. 62/688,636, filed Jun. 22, 2018, each of which is incorporated by reference herein in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 5549626 | Miller et al. | Aug 1996 | A |
| 5885278 | Fleischman | Mar 1999 | A |
| 5928260 | Chin et al. | Jul 1999 | A |
| 5972019 | Engelson et al. | Oct 1999 | A |
| 6022336 | Zadno-Azizi et al. | Feb 2000 | A |
| 6059779 | Mills | May 2000 | A |
| 6315794 | Richter | Nov 2001 | B1 |
| 6540733 | Constantz et al. | Apr 2003 | B2 |
| 6658288 | Hayashi | Dec 2003 | B1 |
| 6663650 | Sepetka et al. | Dec 2003 | B2 |
| 7094249 | Broome et al. | Aug 2006 | B1 |
| 7520966 | Diaz et al. | Apr 2009 | B2 |
| 7556624 | Laufer et al. | Jul 2009 | B2 |
| 8032222 | Loushin et al. | Oct 2011 | B2 |
| 8038674 | Schmaltz et al. | Oct 2011 | B2 |
| 8246641 | Osborne et al. | Aug 2012 | B2 |
| 8382821 | Richter | Feb 2013 | B2 |
| 8603014 | Alleman et al. | Dec 2013 | B2 |
| 8795305 | Martin et al. | Aug 2014 | B2 |
| 8837800 | Bammer et al. | Sep 2014 | B1 |
| 8888788 | Adams et al. | Nov 2014 | B2 |
| 8965534 | Hyatt et al. | Feb 2015 | B2 |
| 9011431 | Long et al. | Apr 2015 | B2 |
| 9039753 | Thramann | May 2015 | B2 |
| 9119656 | Bose et al. | Sep 2015 | B2 |
| 9126018 | Garrison | Sep 2015 | B1 |
| 9179971 | Kirschenman | Nov 2015 | B2 |
| 9211132 | Bowman | Dec 2015 | B2 |
| 9241699 | Kume et al. | Jan 2016 | B1 |
| 9265512 | Garrison et al. | Feb 2016 | B2 |
| 9308007 | Cully et al. | Apr 2016 | B2 |
| 9399118 | Kume et al. | Jul 2016 | B2 |
| 9445828 | Turjman et al. | Sep 2016 | B2 |
| 9445829 | Brady et al. | Sep 2016 | B2 |
| 9492637 | Garrison et al. | Nov 2016 | B2 |
| 9539022 | Bowman | Jan 2017 | B2 |
| 9561345 | Garrison et al. | Feb 2017 | B2 |
| 9579119 | Cully et al. | Feb 2017 | B2 |
| 9585741 | Ma | Mar 2017 | B2 |
| 9642635 | Vale et al. | May 2017 | B2 |
| 9655633 | Leynov et al. | May 2017 | B2 |
| 9681882 | Wilson et al. | Jun 2017 | B2 |
| 9713730 | Mathur et al. | Jul 2017 | B2 |
| 9737318 | Monstadt et al. | Aug 2017 | B2 |
| 9770251 | Bowman et al. | Sep 2017 | B2 |
| 9795400 | Davidson | Oct 2017 | B2 |
| 9801643 | Hansen et al. | Oct 2017 | B2 |
| 9808271 | Ulm | Nov 2017 | B2 |
| 9827084 | Bonnette et al. | Nov 2017 | B2 |
| 9861783 | Garrison et al. | Jan 2018 | B2 |
| 9901543 | Chausson et al. | Feb 2018 | B2 |
| 9993257 | Losordo et al. | Jun 2018 | B2 |
| 10028782 | Orion | Jul 2018 | B2 |
| 10029008 | Creighton | Jul 2018 | B2 |
| 10039906 | Kume et al. | Aug 2018 | B2 |
| 10092241 | Toth et al. | Oct 2018 | B2 |
| 10136942 | Cosman | Nov 2018 | B1 |
| 10251569 | Burkett | Apr 2019 | B2 |
| 10413309 | Farhat et al. | Sep 2019 | B2 |
| 10847411 | Chen et al. | Nov 2020 | B2 |
| 10874411 | Nguyen et al. | Dec 2020 | B2 |
| 10987117 | Girdhar et al. | Apr 2021 | B2 |
| 11058444 | Girdhar et al. | Jul 2021 | B2 |
| 11090071 | Girdhar | Aug 2021 | B2 |
| 11160571 | Nguyen et al. | Nov 2021 | B2 |
| 11666350 | Nguyen et al. | Jun 2023 | B2 |
| 20010001314 | Davison et al. | May 2001 | A1 |
| 20020059938 | Fogarty et al. | May 2002 | A1 |
| 20020091407 | Zadno-Azizi et al. | Jul 2002 | A1 |
| 20020133111 | Shadduck et al. | Sep 2002 | A1 |
| 20030088245 | Woloszko et al. | May 2003 | A1 |
| 20040219660 | Dev et al. | Nov 2004 | A1 |
| 20050096647 | Steinke et al. | May 2005 | A1 |
| 20060089638 | Carmel et al. | Apr 2006 | A1 |
| 20080042662 | Abraham | Feb 2008 | A1 |
| 20080045881 | Teitelbaum et al. | Feb 2008 | A1 |
| 20080262489 | Steinke et al. | Oct 2008 | A1 |
| 20080294181 | Wensel et al. | Nov 2008 | A1 |
| 20080300571 | Lepivert | Dec 2008 | A1 |
| 20090024154 | Williams et al. | Jan 2009 | A1 |
| 20090054918 | Henson | Feb 2009 | A1 |
| 20090069828 | Martin et al. | Mar 2009 | A1 |
| 20090198269 | Hannes et al. | Aug 2009 | A1 |
| 20090240250 | Hayashi et al. | Sep 2009 | A1 |
| 20090318892 | Aboytes et al. | Dec 2009 | A1 |
| 20090318943 | Eidenschink et al. | Dec 2009 | A1 |
| 20090318994 | Eidenschink et al. | Dec 2009 | A1 |
| 20100004623 | Hamilton et al. | Jan 2010 | A1 |
| 20100010533 | Burke et al. | Jan 2010 | A1 |
| 20100042136 | Berrada et al. | Feb 2010 | A1 |
| 20100168739 | Wu et al. | Jul 2010 | A1 |
| 20100174309 | Fulkerson et al. | Jul 2010 | A1 |
| 20100228280 | Groothuis et al. | Sep 2010 | A1 |
| 20100256616 | Katoh et al. | Oct 2010 | A1 |
| 20100256627 | Ma et al. | Oct 2010 | A1 |
| 20110196478 | Torosoff | Aug 2011 | A1 |
| 20110202085 | Loganathan et al. | Aug 2011 | A1 |
| 20110301506 | Volz | Dec 2011 | A1 |
| 20110301549 | Hartmann | Dec 2011 | A1 |
| 20110301594 | Orion et al. | Dec 2011 | A1 |
| 20130008780 | Andreacchi et al. | Jan 2013 | A1 |
| 20130030461 | Marks et al. | Jan 2013 | A1 |
| 20130072960 | Schneider et al. | Mar 2013 | A1 |
| 20130184702 | Neal et al. | Jul 2013 | A1 |
| 20130237864 | Mazar et al. | Sep 2013 | A1 |
| 20130281788 | Garrison | Oct 2013 | A1 |
| 20130282084 | Mathur et al. | Oct 2013 | A1 |
| 20130345739 | Brady et al. | Dec 2013 | A1 |
| 20140025069 | Willard et al. | Jan 2014 | A1 |
| 20140025152 | Headley | Jan 2014 | A1 |
| 20140172001 | Becking et al. | Jun 2014 | A1 |
| 20140188127 | Dubrul et al. | Jul 2014 | A1 |
| 20140265030 | Janardhan et al. | Sep 2014 | A1 |
| 20140276074 | Warner | Sep 2014 | A1 |
| 20140276778 | McLawhorn et al. | Sep 2014 | A1 |
| 20140277013 | Sepetka et al. | Sep 2014 | A1 |
| 20140277079 | Vale et al. | Sep 2014 | A1 |
| 20140309673 | Dacuycuy et al. | Oct 2014 | A1 |
| 20140309675 | Maisano et al. | Oct 2014 | A1 |
| 20140343595 | Monstadt et al. | Nov 2014 | A1 |
| 20140364896 | Consigny | Dec 2014 | A1 |
| 20150112321 | Cadouri | Apr 2015 | A1 |
| 20150133990 | Davidson | May 2015 | A1 |
| 20150150672 | Ma | Jun 2015 | A1 |
| 20150164666 | Johnson et al. | Jun 2015 | A1 |
| 20150182740 | Mickelsen | Jul 2015 | A1 |
| 20150230820 | Turjman et al. | Aug 2015 | A1 |
| 20150297251 | Sos | Oct 2015 | A1 |
| 20150359547 | Vale et al. | Dec 2015 | A1 |
| 20160008003 | Kleshinski et al. | Jan 2016 | A1 |
| 20160015402 | Brady et al. | Jan 2016 | A1 |
| 20160015935 | Chan et al. | Jan 2016 | A1 |
| 20160106448 | Brady et al. | Apr 2016 | A1 |
| 20160106449 | Brady et al. | Apr 2016 | A1 |
| 20160113663 | Brady et al. | Apr 2016 | A1 |
| 20160113665 | Brady et al. | Apr 2016 | A1 |
| 20160151618 | Powers et al. | Jun 2016 | A1 |
| 20160157843 | Dickson et al. | Jun 2016 | A1 |
| 20160157985 | Vo et al. | Jun 2016 | A1 |
| 20160199620 | Pokorney et al. | Jul 2016 | A1 |
| 20160228681 | Di Palma et al. | Aug 2016 | A1 |
| 20160228684 | Martin | Aug 2016 | A1 |
| 20160242661 | Fischell et al. | Aug 2016 | A1 |
| 20160296690 | Kume et al. | Oct 2016 | A1 |
| 20160302808 | Loganathan et al. | Oct 2016 | A1 |
| 20160331377 | Divino et al. | Nov 2016 | A1 |
| 20160375180 | Anzai | Dec 2016 | A1 |
| 20170079766 | Wang et al. | Mar 2017 | A1 |
| 20170079767 | Leon-Yip | Mar 2017 | A1 |
| 20170086862 | Vale et al. | Mar 2017 | A1 |
| 20170100143 | Grandfield | Apr 2017 | A1 |
| 20170105743 | Vale et al. | Apr 2017 | A1 |
| 20170164963 | Goyal | Jun 2017 | A1 |
| 20170172644 | Butzbacker et al. | Jun 2017 | A1 |
| 20170215902 | Leynov et al. | Aug 2017 | A1 |
| 20170215955 | Hancock et al. | Aug 2017 | A1 |
| 20170224953 | Tran et al. | Aug 2017 | A1 |
| 20170281909 | Northrop et al. | Oct 2017 | A1 |
| 20170290599 | Youn et al. | Oct 2017 | A1 |
| 20170367707 | Divino | Dec 2017 | A1 |
| 20180049762 | Seip et al. | Feb 2018 | A1 |
| 20180084982 | Yamashita et al. | Mar 2018 | A1 |
| 20180116717 | Taff et al. | May 2018 | A1 |
| 20180132876 | Zaidat | May 2018 | A1 |
| 20180133436 | Garrison et al. | May 2018 | A1 |
| 20180140314 | Goyal et al. | May 2018 | A1 |
| 20180140315 | Bowman et al. | May 2018 | A1 |
| 20180140354 | Lam et al. | May 2018 | A1 |
| 20180161514 | Rothenberg et al. | Jun 2018 | A1 |
| 20180161541 | Haldis et al. | Jun 2018 | A1 |
| 20180185614 | Garrison et al. | Jul 2018 | A1 |
| 20180200040 | Wasdyke et al. | Jul 2018 | A1 |
| 20180236221 | Opie et al. | Aug 2018 | A1 |
| 20180303595 | Opie et al. | Oct 2018 | A1 |
| 20180344970 | Kornowski et al. | Dec 2018 | A1 |
| 20190038438 | John et al. | Feb 2019 | A1 |
| 20190046119 | Oxley | Feb 2019 | A1 |
| 20190175199 | Girdhar et al. | Jun 2019 | A1 |
| 20190175200 | Girdhar et al. | Jun 2019 | A1 |
| 20190262069 | Taff et al. | Aug 2019 | A1 |
| 20190388097 | Girdhar et al. | Dec 2019 | A1 |
| 20190388107 | Girdhar et al. | Dec 2019 | A1 |
| 20190388111 | Nguyen et al. | Dec 2019 | A1 |
| 20190388112 | Nguyen et al. | Dec 2019 | A1 |
| 20200054392 | Whiteley et al. | Feb 2020 | A1 |
| 20200129742 | Cope et al. | Apr 2020 | A1 |
| 20200297367 | Girdhar et al. | Sep 2020 | A1 |
| 20200297410 | Nguyen et al. | Sep 2020 | A1 |
| 20200390455 | Nguyen et al. | Dec 2020 | A1 |
| 20200390456 | Nguyen et al. | Dec 2020 | A1 |
| 20200390457 | Nageswaran et al. | Dec 2020 | A1 |
| 20200390458 | Nguyen et al. | Dec 2020 | A1 |
| 20210068853 | Nguyen et al. | Mar 2021 | A1 |
| 20210137542 | Oxley et al. | May 2021 | A1 |
| 20210177427 | Nguyen et al. | Jun 2021 | A1 |
| 20210177442 | Girdhar et al. | Jun 2021 | A1 |
| 20210177446 | Girdhar et al. | Jun 2021 | A1 |
| 20210186540 | Taff et al. | Jun 2021 | A1 |
| 20210238764 | Tyvoll et al. | Aug 2021 | A1 |
| 20210267612 | Girdhar et al. | Sep 2021 | A1 |
| 20210272676 | Dierl | Sep 2021 | A1 |
| 20220022900 | Nguyen et al. | Jan 2022 | A1 |
| 20220125455 | Girdhar et al. | Apr 2022 | A1 |
| 20220202431 | Davidson et al. | Jun 2022 | A1 |
| 20220218372 | Nguyen et al. | Jul 2022 | A1 |
| 20220236569 | Yamazaki et al. | Jul 2022 | A1 |
| 20220313288 | Janardhan et al. | Oct 2022 | A1 |
| 20220387051 | Girdhar et al. | Dec 2022 | A1 |
| 20220387098 | Girdhar et al. | Dec 2022 | A1 |
| 20230277240 | Wu et al. | Sep 2023 | A1 |
| Number | Date | Country |
|---|---|---|
| 101472685 | Jul 2009 | CN |
| 102753106 | Oct 2012 | CN |
| 104994799 | Oct 2015 | CN |
| 107405160 | Nov 2017 | CN |
| 104884681 | May 2018 | CN |
| 1484025 | Dec 2004 | EP |
| 2319575 | Nov 2013 | EP |
| 2490764 | Sep 2014 | EP |
| 2895645 | Jul 2015 | EP |
| 2967605 | Jan 2016 | EP |
| 3184067 | Jun 2017 | EP |
| 10290805 | Nov 1998 | JP |
| 2014004219 | Jan 2014 | JP |
| 2018118132 | Aug 2018 | JP |
| 20180102877 | Sep 2018 | KR |
| 0035363 | Jun 2000 | WO |
| 2009127037 | Oct 2009 | WO |
| 2010061376 | Jun 2010 | WO |
| 2014079148 | May 2014 | WO |
| 2015141317 | Sep 2015 | WO |
| 2016007388 | Jan 2016 | WO |
| 2016141025 | Sep 2016 | WO |
| 2016198947 | Dec 2016 | WO |
| 2017058696 | Apr 2017 | WO |
| 2017192999 | Nov 2017 | WO |
| 2018019829 | Feb 2018 | WO |
| 2018033401 | Feb 2018 | WO |
| 2018046408 | Mar 2018 | WO |
| 2018127796 | Jul 2018 | WO |
| 2018137029 | Aug 2018 | WO |
| 2018137030 | Aug 2018 | WO |
| 2018145212 | Aug 2018 | WO |
| 2018156813 | Aug 2018 | WO |
| 2018172891 | Sep 2018 | WO |
| WO-2018172891 | Sep 2018 | WO |
| 2018187776 | Oct 2018 | WO |
| 2019102307 | May 2019 | WO |
| 2019246377 | Dec 2019 | WO |
| Entry |
|---|
| Extended European Search Report dated Jul. 15, 2021; European Application No. 18888795.4; 6 pages. |
| International Search Report and Written Opinion dated Feb. 26, 2021; International Application No. PCT/US20/63200; 14 pages. |
| International Search Report and Written Opinion dated May 25, 2020, International Application No. PCT/US20/22463, 10 pages. |
| International Search Report and Written Opinion dated Nov. 3, 2020, International Application No. PCT/US20/70142, 18 pages. |
| Fort, Stephen , et al., “‘Fused-Gold’ vs. ‘Bare’ stainless steel NIRflex stents of the same geometric design in diseased native coronary arteries. Long-term results from the NIR TOP Study”, Euro Interv 2007; 3:256-261. |
| International Search Report and Written Opinion dated Mar. 24, 2022; International Application No. PCT/US2021/061540; 10 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20220022899 A1 | Jan 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62688636 | Jun 2018 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16024408 | Jun 2018 | US |
| Child | 17303208 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 17303208 | May 2021 | US |
| Child | 17450236 | US |
